5 results
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
evaluating the efficacy, safety and tolerability of camlipixant in RCC. Both trials are running concurrently, and each will recruit approximately 675 adult
6-K
EX-99.1
BLU
Bellus Health Inc
29 Mar 23
Current report (foreign)
5:26pm
, and each will recruit approximately 675 adult participants. We expect to report topline data from CALM-1 in the second half of 2024 and from CALM-2
6-K
EX-99.1
BLU
Bellus Health Inc
8 Sep 20
BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough
7:00am
of BLU-5937 in 280 patients with refractory chronic cough –
- Trial to recruit patients with baseline cough count ≥25 coughs per hour -- RELIEF … our plan to recruit patients with baseline cough frequencies25 coughs per hour for the SOOTHE trial provides the best strategy for success
6-K
BLU
Bellus Health Inc
3 Apr 07
Current report (foreign)
12:00am
is of a similar design to the North American clinical trial and is expected to recruit approximately 930 mild-to-moderate AD patients at about 70 clinical
6-K
BLU
Bellus Health Inc
1 Feb 07
Current report (foreign)
12:00am
and is expected to recruit approximately 930 mild-to-moderate AD patients at more than 70 clinical centers in 10 European countries. The enrolment
- Prev
- 1
- Next